Stockreport

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring [Yahoo! Finance]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Launches of Rebyota ® and Adstiladrin ® in United States provide major mid- to -long-term opportunities for the company to diversify into new therapeutic areas Signif [Read more]